Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.
Oncology professionals reflect on the unique value of attending the American Society of Clinical Oncology (ASCO) annual meeting—from discovering new clinical trial results to reconnecting with peers from around the world. With major practice-changing research and global thought leadership in one place, ASCO continues to be a can't-miss event for the cancer care community.
Here is what the following attendees who spoke with The American Journal of Managed Care® had to say about the event:
This transcript was lightly edited; captions were auto-generated.
Transcript
What is your favorite thing about attending ASCO?
Arnold: It’s always about learning, and learning is so great, so that’s a great week of oncology. We can learn so much about new trials, new results which come out, and also new strategies for our patients. And of course, it’s also networking. It’s meeting with colleagues and friends. So therefore, it’s always a great week—in this year and every year. And yeah, hopefully we’ll all have a great and joyful and super exciting ASCO.
Picozzi: Well, I like Italian food, so Chicago is always good for that. But really, the thing I like about ASCO is getting to see my colleagues and peers from around the country and around the world. It’s probably the best place to engage other thought leaders, and so I really look forward to seeing my colleagues worldwide every year.
Rischin: I’ve been coming to ASCO regularly over the last 25 years or so. I think the key thing is that at the meeting, major findings of new studies—studies that change clinical practice—are presented. It’s an opportunity to interact with your colleagues and discuss new findings. It’s a stimulating opportunity to interact and learn more about new treatments.
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges
June 4th 2025Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and unmet needs for effective third-line treatments, highlighting urgent care gaps.
Read More